Lymphodepletion

DRUG3 trials

Conditions

B-cell Lymphoma RecurrentB-cell Lymphoma RefractoryEpithelial Ovarian CancerGastro-esophageal Junction CancerMetastatic MelanomaMyxoid LiposarcomaSoft Tissue Sarcoma (STS)Synovial Sarcoma

Phase 1

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Not yet recruitingNCT06748872

Medigene AGEpithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Myxoid Liposarcoma +2

Start: 2025-07-01End: 2042-08-01Target: 55Updated: 2024-12-27

Phase 2

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

CompletedNCT01659151

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Melanoma

Start: 2012-08-03End: 2025-08-19Updated: 2026-02-20

Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

TerminatedNCT06912529

Universität MünsterB-cell Lymphoma Recurrent, B-cell Lymphoma Refractory

Start: 2025-03-13End: 2025-07-25Updated: 2025-09-04

Blood2025-11-03

CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

Journal for ImmunoTherapy of Cancer2025-04-016 citations

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

385 Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL)

Regular and Young Investigator Award Abstracts2021-11-01

Lymphodepletion

Sponsors

Conditions

Phase 1

Phase 2

Related Papers